John Redwood
Main Page: John Redwood (Conservative - Wokingham)I thank my hon. Friend the Member for Oxford West and Abingdon (Nicola Blackwood) for her Select Committee’s important work. I will use the time available to address some of the concerns of the Science and Technology Committee and to respond to some of the points made by hon. Members.
First, it is right to remind ourselves of and to celebrate the landscape in which the Government’s plan for science and research lies. As hon. Members have mentioned, the UK’s global scientific impact far exceeds our size as a nation. With just 3.2% of the world’s R and D spend, the UK accounts for 16% of the most highly cited research articles—we have overtaken the US to rank first among comparable research nations for our field-weighted citations impact—of which we should all be extremely proud.
That is why science and research very much sit at the very heart of this Government’s economic plan. Last July, our productivity plan clearly set out how we will tackle the UK’s long-term productivity problem, with science and research being central to our proposed solutions. This autumn’s spending review settlement was an emphatic confirmation of that commitment: an extension of the ring fence around science and innovation until 2020 means a total investment of £30.4 billion during this Parliament.
The ring fence has been a powerful indication of the Government’s commitment to science, and we will continue to protect science resource funding in real terms for the rest of the Parliament. We are building on the safeguards put in place for the science budget in the last Parliament. That will mean a decade of protection and of sustained investment by the Government. All that of course comes in the context of significant savings in other areas of Government expenditure, which is a clear sign of the important place of science in our decision making.
The Science and Technology Committee has called for a road map towards a 3% R and D spend. As my hon. Friend the Member for Oxford West and Abingdon knows, decisions on increases in the science spend are taken in spending reviews, when it is weighed up against the other priorities for the nation. My hon. Friend the Chair of the Science and Technology Committee also asked about allocations. We have discussed indicative allocations with our partner organisations. They are very much aware of their likely settlements, and I assure her that we will publish the allocations imminently.
My hon. Friend asked about the next steps in the implementation of the Nurse review and our thinking about the proposals we outlined in the Green Paper. As I am sure she will have appreciated, we consulted very carefully on how best to proceed, with a proper 10-week consultation. Although I understand her impatience to know how we will take all the proposals forward, it is important that we do so in a deliberative fashion and get these important decisions absolutely right. The consultation period ended only on 15 January and we will come forward with our full response in the spring.
In the meantime, I hope that I can give my hon. Friend the assurance she seeks from the Government by saying that we will maintain the spirit of the dual support system, which is so important to our research sector, alongside the continuation of the important Haldane principle, which ensures that decisions about which research to fund are taken by scientists through competitive peer review processes. To deal with her concerns about the operation of the dual support system in a bit more detail, it is possible to ring-fence or hypothecate separate funding streams, even when they are delivered through a single body. That is a model that the Government can and do use effectively, and that could ensure the continuation of the dual support system in a reshaped landscape.
The Chair of the Business, Innovation and Skills Committee, the hon. Member for Hartlepool (Mr Wright) raised concerns about the move from grants to loans which were echoed by the Opposition spokesperson, the hon. Member for Makerfield (Yvonne Fovargue) and by the hon. Member for Glasgow North West (Carol Monaghan). We will market-test the proposed new financial products in the spring. We want to broaden the types of financial support that are available for innovation in this country. BIS and Innovate UK are studying the financial models that are operated by our international counterparts in respect of innovation. It is clear from our analysis of what is going on around the world that the most successful models are increasingly emphasising other financial products in their policy mix as a supplement to their grant funding, which will always have a place.
We want to ensure that the overall funding through Innovate UK evolves and that the spectrum of products diversifies to reflect the different needs of different companies at different stages in their lifecycle. Overall funding will increase from £311 million in 2009-10 to £471 million by 2019-20. That figure includes the new finance products.
My hon. Friend the Member for Bolton West (Chris Green) rightly echoed the Dowling report’s recommendation that we seek greater simplification of the innovation landscape and support system. We will certainly take that core recommendation into account as we develop the thinking on our national innovation plan.
I want to emphasise three commitments in the spending review and ensure that the House understands their importance. The first is our commitment to protect science resource funding at £4.7 billion. This is the lifeblood that powers our world-leading science and research base. It funds vital blue-skies research, fuels the Bunsen burners and afterburners, and funds labs up and down the country, the research councils and the national academies, thereby making sure that Britain stays at the leading edge of global science.
At the same time, we are delivering on our manifesto commitment and investing in new commitments on a record scale, with £6.9 billion for capital expenditure. That means new research institutes and laboratories across the UK. It has been one of the greatest privileges as Science Minister to break ground on new institutions such as the imaging centre of excellence at the Queen Elizabeth university hospital in Glasgow. To answer the hon. Member for Glasgow North West, I hope that that demonstrates the Government’s commitment to ensuring that we fund excellent science wherever it is found in the United Kingdom.
Through our science and innovation audit, we want to encourage areas that have not received much science funding relative to other areas to come forward with proposals that we can support when we feel that they have the potential to be excellent and to do great science. We want more such proposals.
The third matter that I want to consider is the global challenges research fund. We have committed an additional £1.5 billion to the fund by 2021. It will keep the UK at the forefront of global research, leading the way on major global challenges, such as Ebola, in which we have always played a significant role. The value of the GCRF is not just what the UK can do alone. We have some of the world’s most talented scientists, most prestigious universities and most advanced laboratories, but the most significant breakthroughs in science and research are bigger than just one country.
That brings me to the points that the hon. Member for Stoke-on-Trent Central (Tristram Hunt) made. I am glad to have his general support for all the spending review commitments that I have briefly summarised. They will give the science community the certainty that it needs for the years ahead. Like the hon. Gentleman, I recognise the important role that public sector investment in science plays in stimulating private sector investment. Other Members have already cited the crowding-in effect, which we estimate at about £1.36 for every £1 of public investment.
The hon. Member for Stoke-on-Trent Central is also clearly right about Europe. Science today is increasingly cross-border and collaborative. I have made my position clear, as have the Government: UK universities and our superb science base are key to our future as a knowledge economy, and we and they will be much stronger inside the EU. That is best for our research. Almost half of all UK research publications involve collaborations with other countries. Papers involving international collaboration have almost twice the citation impact of those produced by a single UK author, and EU countries are among our most crucial partners, representing nearly 50% of all our overseas collaborators.
Staying in the EU is best for our students. Our links with Europe are deep and long standing. Free movement of people makes it easier for our universities to attract the best talent, and for British students to spread their wings across the continent. Lastly, it is best for our funding. The excellence of our research base means that it is no surprise that the UK is one of the most successful players in EU research programmes.
Is not it the case that we collaborate a great deal with the United States of America, which is not a member of the European Union? Would not any British Government want freedom of movement of expert people to our universities, whether we were in or out of the EU?
My right hon. Friend is right—the partnerships are not exclusive, but why turn our back on great collaborations that benefit our science base tremendously?
The UK received €7 billion under the last framework programme, which ran from 2007 to 2013. That made us one of the largest beneficiaries of EU research funding. In this funding round, Horizon 2020, we have secured 15.4% of funds, behind only Germany on 16.5%, and with the second largest number of project participations.
As science becomes more international, we should nurture partnerships, not reject them. In the end, the British people will decide whether we are safer, stronger and better off as part of the EU, but, to thrive in a knowledge economy, there is no doubt that we need to build academic partnerships, not turn our backs on them.